Clinical trial

A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients

NCT00360334

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2006-06-01

PhasePHASE3

Study timeline

Study start (unknown)2006-06-01Date precision: month

Registry last updated2015-04-07

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 2 Diabetesunresolved

Interventions

exenatideDRUG · verified · RxNorm: exenatide

insulin glargineDRUG · verified · RxNorm: insulin glargine

Sponsors & collaborators

AstraZenecalead sponsor

Eli Lilly and Companycollaborator

Mapped research locations

LondonUnited Kingdom1 ManchesterUnited Kingdom1 GlasgowUnited Kingdom1 NottinghamUnited Kingdom1 LiverpoolUnited Kingdom1 EdinburghUnited Kingdom1 LeicesterUnited Kingdom1 OxfordUnited Kingdom1 BristolUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00360334 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.